Attributes | Values |
---|
rdf:type
| |
rdfs:seeAlso
| |
Description
| - We analyzed efficacy and safety of imatinib in the first line therapy of 152 consecutive adult patients with chronic myeloid leukemia diagnosed in chronic phase from a defined region. We confirmed very good efficacy and safety of imatinib also in non-study patients treated in experienced centers. More appropriate selection of end-points in survival analyses is desirable to describe the real efficacy of imatinib and other TKIs.
- We analyzed efficacy and safety of imatinib in the first line therapy of 152 consecutive adult patients with chronic myeloid leukemia diagnosed in chronic phase from a defined region. We confirmed very good efficacy and safety of imatinib also in non-study patients treated in experienced centers. More appropriate selection of end-points in survival analyses is desirable to describe the real efficacy of imatinib and other TKIs. (en)
|
Title
| - Imatinib as the first line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?
- Imatinib as the first line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials? (en)
|
skos:prefLabel
| - Imatinib as the first line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?
- Imatinib as the first line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials? (en)
|
skos:notation
| - RIV/00023736:_____/11:00008834!RIV12-MZ0-00023736
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00023736:_____/11:00008834
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - chronic myeloid leukemia; chronic phase; Imatinib (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - American Journal of Hematology
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Březinová, Jana
- Cetkovský, Petr
- Dušek, L.
- Dvořáková, D.
- Klamová, Hana
- Mayer, J.
- Michalová, Kyra
- Moravcová, Jana
- Ráčil, Z.
- Rázga, F.
- Trněný, Marek
- Machová Poláková, Kateřina
- Doubek, M.
- Jurček, T.
- Mužík, J.
- Oltová, A.
- Pospíšil, Z.
- Žáčková, D.
|
http://linked.open...ain/vavai/riv/wos
| |
issn
| |
number of pages
| |
http://bibframe.org/vocab/doi
| |